Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. ZYNE Peers
See (ZYNE) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZYNE | $1.30 | +2.36% | 70.1M | -1.65 | -$0.79 | N/A |
| ZTS | $157.31 | -0.29% | 70B | 28.29 | $5.56 | +1.18% |
| HLN | $10.51 | +0.14% | 47.2B | 25.01 | $0.42 | +1.11% |
| TAK | $14.99 | -0.63% | 47.2B | 65.15 | $0.23 | +3.92% |
| TEVA | $17.01 | -0.50% | 19.5B | -14.79 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.49 | -0.64% | 12.9B | 19.86 | $0.78 | +0.62% |
| NBIX | $127.78 | -0.31% | 12.6B | 43.32 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.5B | -27.84 | -$2.28 | N/A |
| RGC | $21.73 | -5.32% | 10.7B | -2173.00 | -$0.01 | N/A |
Stock Comparison
ZYNE vs ZTS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ZTS has a market cap of 70B. Regarding current trading prices, ZYNE is priced at $1.30, while ZTS trades at $157.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ZTS's P/E ratio is 28.29. In terms of profitability, ZYNE's ROE is -0.59%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ZYNE is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs HLN Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HLN has a market cap of 47.2B. Regarding current trading prices, ZYNE is priced at $1.30, while HLN trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HLN's P/E ratio is 25.01. In terms of profitability, ZYNE's ROE is -0.59%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ZYNE is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TAK Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TAK has a market cap of 47.2B. Regarding current trading prices, ZYNE is priced at $1.30, while TAK trades at $14.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TAK's P/E ratio is 65.15. In terms of profitability, ZYNE's ROE is -0.59%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ZYNE is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TEVA Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TEVA has a market cap of 19.5B. Regarding current trading prices, ZYNE is priced at $1.30, while TEVA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TEVA's P/E ratio is -14.79. In terms of profitability, ZYNE's ROE is -0.59%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ZYNE is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ITCI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZYNE is priced at $1.30, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZYNE's ROE is -0.59%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs RDY Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RDY has a market cap of 12.9B. Regarding current trading prices, ZYNE is priced at $1.30, while RDY trades at $15.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RDY's P/E ratio is 19.86. In terms of profitability, ZYNE's ROE is -0.59%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ZYNE is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs NBIX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, NBIX has a market cap of 12.6B. Regarding current trading prices, ZYNE is priced at $1.30, while NBIX trades at $127.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas NBIX's P/E ratio is 43.32. In terms of profitability, ZYNE's ROE is -0.59%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ZYNE is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CTLT Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZYNE is priced at $1.30, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZYNE's ROE is -0.59%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ZYNE is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs RGC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RGC has a market cap of 10.7B. Regarding current trading prices, ZYNE is priced at $1.30, while RGC trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RGC's P/E ratio is -2173.00. In terms of profitability, ZYNE's ROE is -0.59%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ZYNE is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs VTRS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, VTRS has a market cap of 10.4B. Regarding current trading prices, ZYNE is priced at $1.30, while VTRS trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas VTRS's P/E ratio is -2.80. In terms of profitability, ZYNE's ROE is -0.59%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ZYNE is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ELAN Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ELAN has a market cap of 6.8B. Regarding current trading prices, ZYNE is priced at $1.30, while ELAN trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ELAN's P/E ratio is 18.35. In terms of profitability, ZYNE's ROE is -0.59%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ZYNE is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs LNTH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, ZYNE is priced at $1.30, while LNTH trades at $80.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LNTH's P/E ratio is 22.96. In terms of profitability, ZYNE's ROE is -0.59%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZYNE is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AMRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AMRX has a market cap of 3.7B. Regarding current trading prices, ZYNE is priced at $1.30, while AMRX trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AMRX's P/E ratio is -201.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PRGO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, ZYNE is priced at $1.30, while PRGO trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PRGO's P/E ratio is -22.20. In terms of profitability, ZYNE's ROE is -0.59%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ZYNE is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ALVO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, ZYNE is priced at $1.30, while ALVO trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ALVO's P/E ratio is 24.68. In terms of profitability, ZYNE's ROE is -0.59%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ZYNE is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs HCM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, ZYNE is priced at $1.30, while HCM trades at $15.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HCM's P/E ratio is 77.45. In terms of profitability, ZYNE's ROE is -0.59%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ALVOW Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, ZYNE is priced at $1.30, while ALVOW trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ZYNE's ROE is -0.59%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ZYNE is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs BGM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BGM has a market cap of 2.4B. Regarding current trading prices, ZYNE is priced at $1.30, while BGM trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BGM's P/E ratio is -65.00. In terms of profitability, ZYNE's ROE is -0.59%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ZYNE is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs BHC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ZYNE is priced at $1.30, while BHC trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BHC's P/E ratio is -53.17. In terms of profitability, ZYNE's ROE is -0.59%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs DCPH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZYNE is priced at $1.30, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZYNE's ROE is -0.59%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, ZYNE is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EMBCV Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZYNE is priced at $1.30, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZYNE's ROE is -0.59%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ZYNE is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SUPN Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, ZYNE is priced at $1.30, while SUPN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SUPN's P/E ratio is 28.14. In terms of profitability, ZYNE's ROE is -0.59%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ZYNE is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs INDV Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, INDV has a market cap of 1.7B. Regarding current trading prices, ZYNE is priced at $1.30, while INDV trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas INDV's P/E ratio is -274.60. In terms of profitability, ZYNE's ROE is -0.59%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ZYNE is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TARO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZYNE is priced at $1.30, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZYNE's ROE is -0.59%, compared to TARO's ROE of +0.02%. Regarding short-term risk, ZYNE is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EVO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, ZYNE is priced at $1.30, while EVO trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EVO's P/E ratio is -6.21. In terms of profitability, ZYNE's ROE is -0.59%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ZYNE is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ANIP Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, ZYNE is priced at $1.30, while ANIP trades at $66.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ANIP's P/E ratio is -55.95. In terms of profitability, ZYNE's ROE is -0.59%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ZYNE is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs DVAX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, ZYNE is priced at $1.30, while DVAX trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DVAX's P/E ratio is -19.72. In terms of profitability, ZYNE's ROE is -0.59%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZYNE is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs HROW Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ZYNE is priced at $1.30, while HROW trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HROW's P/E ratio is -51.72. In terms of profitability, ZYNE's ROE is -0.59%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ZYNE is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PCRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, ZYNE is priced at $1.30, while PCRX trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PCRX's P/E ratio is -10.67. In terms of profitability, ZYNE's ROE is -0.59%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ZYNE is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AMPH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, ZYNE is priced at $1.30, while AMPH trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AMPH's P/E ratio is 8.50. In terms of profitability, ZYNE's ROE is -0.59%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ZYNE is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PAHC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PAHC has a market cap of 1B. Regarding current trading prices, ZYNE is priced at $1.30, while PAHC trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PAHC's P/E ratio is 31.73. In terms of profitability, ZYNE's ROE is -0.59%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ZYNE is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs COLL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, COLL has a market cap of 957.5M. Regarding current trading prices, ZYNE is priced at $1.30, while COLL trades at $29.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas COLL's P/E ratio is 24.42. In terms of profitability, ZYNE's ROE is -0.59%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ZYNE is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PETQ Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZYNE is priced at $1.30, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZYNE's ROE is -0.59%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AVDL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AVDL has a market cap of 914.2M. Regarding current trading prices, ZYNE is priced at $1.30, while AVDL trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AVDL's P/E ratio is -36.29. In terms of profitability, ZYNE's ROE is -0.59%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ZYNE is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CRON Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CRON has a market cap of 730.4M. Regarding current trading prices, ZYNE is priced at $1.30, while CRON trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CRON's P/E ratio is 13.54. In terms of profitability, ZYNE's ROE is -0.59%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EOLS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EOLS has a market cap of 586.7M. Regarding current trading prices, ZYNE is priced at $1.30, while EOLS trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EOLS's P/E ratio is -10.22. In terms of profitability, ZYNE's ROE is -0.59%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ZYNE is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EMBC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EMBC has a market cap of 580.3M. Regarding current trading prices, ZYNE is priced at $1.30, while EMBC trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EMBC's P/E ratio is 11.16. In terms of profitability, ZYNE's ROE is -0.59%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs BDSI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZYNE is priced at $1.30, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZYNE's ROE is -0.59%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZYNE is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SIGA Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SIGA has a market cap of 460.1M. Regarding current trading prices, ZYNE is priced at $1.30, while SIGA trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SIGA's P/E ratio is 9.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ZYNE is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs KMDA Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, KMDA has a market cap of 451.1M. Regarding current trading prices, ZYNE is priced at $1.30, while KMDA trades at $7.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas KMDA's P/E ratio is 28.02. In terms of profitability, ZYNE's ROE is -0.59%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ZYNE is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ORGO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ORGO has a market cap of 449.1M. Regarding current trading prices, ZYNE is priced at $1.30, while ORGO trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ORGO's P/E ratio is -22.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ZYNE is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TLRY Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TLRY has a market cap of 403.9M. Regarding current trading prices, ZYNE is priced at $1.30, while TLRY trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TLRY's P/E ratio is -0.37. In terms of profitability, ZYNE's ROE is -0.59%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ZYNE is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ZYBT Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ZYBT has a market cap of 373.2M. Regarding current trading prices, ZYNE is priced at $1.30, while ZYBT trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ZYBT's P/E ratio is 131.25. In terms of profitability, ZYNE's ROE is -0.59%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ZYNE is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EBS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EBS has a market cap of 364.7M. Regarding current trading prices, ZYNE is priced at $1.30, while EBS trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EBS's P/E ratio is -2.60. In terms of profitability, ZYNE's ROE is -0.59%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ZYNE is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AQST Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AQST has a market cap of 323.3M. Regarding current trading prices, ZYNE is priced at $1.30, while AQST trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AQST's P/E ratio is -5.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ZYNE is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SNDL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SNDL has a market cap of 313.9M. Regarding current trading prices, ZYNE is priced at $1.30, while SNDL trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SNDL's P/E ratio is -4.07. In terms of profitability, ZYNE's ROE is -0.59%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ZYNE is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs LFCR Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LFCR has a market cap of 308.8M. Regarding current trading prices, ZYNE is priced at $1.30, while LFCR trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LFCR's P/E ratio is -5.67. In terms of profitability, ZYNE's ROE is -0.59%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ZYNE is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ALIM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZYNE is priced at $1.30, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, ZYNE is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TKNO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TKNO has a market cap of 277.4M. Regarding current trading prices, ZYNE is priced at $1.30, while TKNO trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TKNO's P/E ratio is -11.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ZYNE is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs LNDC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZYNE is priced at $1.30, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ZYNE is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CGC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CGC has a market cap of 252.3M. Regarding current trading prices, ZYNE is priced at $1.30, while CGC trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CGC's P/E ratio is -0.29. In terms of profitability, ZYNE's ROE is -0.59%, compared to CGC's ROE of -1.13%. Regarding short-term risk, ZYNE is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TYHT Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZYNE is priced at $1.30, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ZYNE is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ACB Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ACB has a market cap of 214.9M. Regarding current trading prices, ZYNE is priced at $1.30, while ACB trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ACB's P/E ratio is 20.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to ACB's ROE of +0.00%. Regarding short-term risk, ZYNE is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ESPR Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ESPR has a market cap of 200.2M. Regarding current trading prices, ZYNE is priced at $1.30, while ESPR trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ESPR's P/E ratio is -1.19. In terms of profitability, ZYNE's ROE is -0.59%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ZYNE is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs REPH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZYNE is priced at $1.30, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZYNE is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs OGI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, OGI has a market cap of 176.1M. Regarding current trading prices, ZYNE is priced at $1.30, while OGI trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas OGI's P/E ratio is 10.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs DERM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DERM has a market cap of 162.4M. Regarding current trading prices, ZYNE is priced at $1.30, while DERM trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DERM's P/E ratio is -18.84. In terms of profitability, ZYNE's ROE is -0.59%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ZYNE is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs BIOA Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BIOA has a market cap of 153.8M. Regarding current trading prices, ZYNE is priced at $1.30, while BIOA trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BIOA's P/E ratio is -2.17. In terms of profitability, ZYNE's ROE is -0.59%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ZYNE is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs IRWD Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, IRWD has a market cap of 120.5M. Regarding current trading prices, ZYNE is priced at $1.30, while IRWD trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas IRWD's P/E ratio is -3.92. In terms of profitability, ZYNE's ROE is -0.59%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ZYNE is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CRDL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CRDL has a market cap of 119.4M. Regarding current trading prices, ZYNE is priced at $1.30, while CRDL trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CRDL's P/E ratio is -4.25. In terms of profitability, ZYNE's ROE is -0.59%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, ZYNE is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SCTL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZYNE is priced at $1.30, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZYNE's ROE is -0.59%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZYNE is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PROC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ZYNE is priced at $1.30, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZYNE's ROE is -0.59%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZYNE is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs THTX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, THTX has a market cap of 112.2M. Regarding current trading prices, ZYNE is priced at $1.30, while THTX trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas THTX's P/E ratio is -34.86. In terms of profitability, ZYNE's ROE is -0.59%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ZYNE is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs OPTN Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZYNE is priced at $1.30, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZYNE's ROE is -0.59%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ZYNE is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ZOM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZYNE is priced at $1.30, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZYNE's ROE is -0.59%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ZYNE is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs GRVI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZYNE is priced at $1.30, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZYNE's ROE is -0.59%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, ZYNE is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs QNTM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, QNTM has a market cap of 70.9M. Regarding current trading prices, ZYNE is priced at $1.30, while QNTM trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas QNTM's P/E ratio is -1.84. In terms of profitability, ZYNE's ROE is -0.59%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ZYNE is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs INCR Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, INCR has a market cap of 69.8M. Regarding current trading prices, ZYNE is priced at $1.30, while INCR trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas INCR's P/E ratio is -3.52. In terms of profitability, ZYNE's ROE is -0.59%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SSIC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZYNE is priced at $1.30, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZYNE's ROE is -0.59%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, ZYNE is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs VLNS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZYNE is priced at $1.30, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZYNE's ROE is -0.59%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZYNE is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ASRT Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ASRT has a market cap of 60.5M. Regarding current trading prices, ZYNE is priced at $1.30, while ASRT trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ASRT's P/E ratio is -1.97. In terms of profitability, ZYNE's ROE is -0.59%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ZYNE is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs JUPW Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZYNE is priced at $1.30, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZYNE's ROE is -0.59%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ZYNE is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SXTC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SXTC has a market cap of 44.8M. Regarding current trading prices, ZYNE is priced at $1.30, while SXTC trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ZYNE's ROE is -0.59%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ZYNE is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs QLI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZYNE is priced at $1.30, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZYNE's ROE is -0.59%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZYNE is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CPIX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CPIX has a market cap of 38.2M. Regarding current trading prices, ZYNE is priced at $1.30, while CPIX trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CPIX's P/E ratio is -10.62. In terms of profitability, ZYNE's ROE is -0.59%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ZYNE is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs HEXO Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZYNE is priced at $1.30, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZYNE's ROE is -0.59%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZYNE is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs KALA Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, KALA has a market cap of 30.3M. Regarding current trading prices, ZYNE is priced at $1.30, while KALA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas KALA's P/E ratio is -0.64. In terms of profitability, ZYNE's ROE is -0.59%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ZYNE is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs EGRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EGRX has a market cap of 29.8M. Regarding current trading prices, ZYNE is priced at $1.30, while EGRX trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EGRX's P/E ratio is 2.71. In terms of profitability, ZYNE's ROE is -0.59%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ZYNE is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SCYX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SCYX has a market cap of 29.2M. Regarding current trading prices, ZYNE is priced at $1.30, while SCYX trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SCYX's P/E ratio is -1.34. In terms of profitability, ZYNE's ROE is -0.59%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ZYNE is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs RMTI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RMTI has a market cap of 28.4M. Regarding current trading prices, ZYNE is priced at $1.30, while RMTI trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RMTI's P/E ratio is -82.99. In terms of profitability, ZYNE's ROE is -0.59%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ZYNE is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs CYTH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZYNE is priced at $1.30, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZYNE's ROE is -0.59%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ZYNE is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs IXHL Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, IXHL has a market cap of 19.7M. Regarding current trading prices, ZYNE is priced at $1.30, while IXHL trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas IXHL's P/E ratio is -0.17. In terms of profitability, ZYNE's ROE is -0.59%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ZYNE is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs DRRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DRRX has a market cap of 19.2M. Regarding current trading prices, ZYNE is priced at $1.30, while DRRX trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DRRX's P/E ratio is -1.29. In terms of profitability, ZYNE's ROE is -0.59%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ZYNE is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs GELS Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, GELS has a market cap of 18.2M. Regarding current trading prices, ZYNE is priced at $1.30, while GELS trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas GELS's P/E ratio is -8.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to GELS's ROE of -0.21%. Regarding short-term risk, ZYNE is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs FLGC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, FLGC has a market cap of 14.7M. Regarding current trading prices, ZYNE is priced at $1.30, while FLGC trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas FLGC's P/E ratio is -0.68. In terms of profitability, ZYNE's ROE is -0.59%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ZYNE is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ACRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZYNE is priced at $1.30, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZYNE's ROE is -0.59%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ZYNE is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs PRPH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PRPH has a market cap of 14.1M. Regarding current trading prices, ZYNE is priced at $1.30, while PRPH trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PRPH's P/E ratio is -0.15. In terms of profitability, ZYNE's ROE is -0.59%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, ZYNE is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TXMD Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TXMD has a market cap of 13.9M. Regarding current trading prices, ZYNE is priced at $1.30, while TXMD trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TXMD's P/E ratio is -6.32. In terms of profitability, ZYNE's ROE is -0.59%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ZYNE is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AYTU Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AYTU has a market cap of 13.2M. Regarding current trading prices, ZYNE is priced at $1.30, while AYTU trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AYTU's P/E ratio is -1.43. In terms of profitability, ZYNE's ROE is -0.59%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ZYNE is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs COSM Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, ZYNE is priced at $1.30, while COSM trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas COSM's P/E ratio is -0.40. In terms of profitability, ZYNE's ROE is -0.59%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ZYNE is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs AGRX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZYNE is priced at $1.30, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZYNE's ROE is -0.59%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, ZYNE is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs TLPH Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TLPH has a market cap of 9.2M. Regarding current trading prices, ZYNE is priced at $1.30, while TLPH trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TLPH's P/E ratio is -1.02. In terms of profitability, ZYNE's ROE is -0.59%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ZYNE is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs IMCC Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, IMCC has a market cap of 8.5M. Regarding current trading prices, ZYNE is priced at $1.30, while IMCC trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas IMCC's P/E ratio is -2.01. In terms of profitability, ZYNE's ROE is -0.59%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, ZYNE is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs SBFMW Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SBFMW has a market cap of 8.3M. Regarding current trading prices, ZYNE is priced at $1.30, while SBFMW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SBFMW's P/E ratio is -0.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, ZYNE is less volatile compared to SBFMW. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs NLTX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZYNE is priced at $1.30, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ZYNE is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs YCBD Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, YCBD has a market cap of 7.7M. Regarding current trading prices, ZYNE is priced at $1.30, while YCBD trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ZYNE's ROE is -0.59%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, ZYNE is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs LCI Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZYNE is priced at $1.30, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZYNE is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs BGXX Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ZYNE is priced at $1.30, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ZYNE's ROE is -0.59%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ZYNE is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.
ZYNE vs ADMP Comparison
ZYNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZYNE is priced at $1.30, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZYNE's ROE is -0.59%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZYNE is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for ZYNE.